1/2 We maintain control over our only Phase 3 asse
Post# of 30028
(Total Views: 446)
Posted On: 12/29/2018 8:09:09 PM
.jpg)
1/2 We maintain control over our only Phase 3 asset, ESS in Cutanogen Corp. We are selling our Phase 2b asset Eltoprazine to Coeptis Pharma, who is now completing a pre-IPO round ahead of a planned IPO within 12 months of the closing of the transaction.
2/2 We have JV’ed our LymPro asset with Todos $TOMDF for a significant equity stake, and are evaluating options for MANF. We expect the sum of the parts far outweigh our market cap and our enterprise value. The spin-off strategy implemented to reduce parent capital requirements
G's Tweets last night in response to some twitter criticism, for all of you lacking twitter
2/2 We have JV’ed our LymPro asset with Todos $TOMDF for a significant equity stake, and are evaluating options for MANF. We expect the sum of the parts far outweigh our market cap and our enterprise value. The spin-off strategy implemented to reduce parent capital requirements
G's Tweets last night in response to some twitter criticism, for all of you lacking twitter
(5)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼